![Robert Smith](https://cdn.zonebourse.com/static/resize/768/576//static/images/insiders/unknown.png)
Robert Smith
Directeur/Membre du Conseil chez CITIUS PHARMACEUTICALS, INC.
Profil
Robert J.
Smith is currently an Independent Director at Citius Pharmaceuticals, Inc. and the President at Bamboo Therapeutics, Inc. He has an MBA from the University of Rochester Simon Business School and an undergraduate degree from Rochester Christian University.
Postes actifs de Robert Smith
Sociétés | Poste | Début |
---|---|---|
CITIUS PHARMACEUTICALS, INC. | Directeur/Membre du Conseil | 12/03/2024 |
Bamboo Therapeutics, Inc.
![]() Bamboo Therapeutics, Inc. BiotechnologyHealth Technology Bamboo Therapeutics, Inc. develops gene therapy products for central nervous system and neuromuscular diseases. Its therapeutic platform is based on the use of Adeno-associated virus as a gene therapy vehicle. The company’s proprietary technologies include chimeric vectors, self-complementary vectors, and dual glycan receptor. It focuses on the treatment of Duchenne muscular dystrophy, giant axonal neuropathy, Friedreich ataxia, and Canavan disease. Bamboo Therapeutics was founded by Richard Jude Samulski, Sheila A. Mikhail, Josh Grieger, Xiao Xiao, and Paola Leone in December 2014 and is headquartered in Chapel Hill, NC. | President | - |
Formation de Robert Smith
Rochester Christian University | Undergraduate Degree |
University of Rochester Simon Business School | Masters Business Admin |
Expériences
Fonctions occupées
Relations
Relations au 1er degré
Entreprises liées au 1er degré
Homme
Femme
Administrateurs
Exécutifs
Sociétés liées
Sociétés cotées | 1 |
---|---|
CITIUS PHARMACEUTICALS, INC. | Health Technology |
Entreprise privées | 1 |
---|---|
Bamboo Therapeutics, Inc.
![]() Bamboo Therapeutics, Inc. BiotechnologyHealth Technology Bamboo Therapeutics, Inc. develops gene therapy products for central nervous system and neuromuscular diseases. Its therapeutic platform is based on the use of Adeno-associated virus as a gene therapy vehicle. The company’s proprietary technologies include chimeric vectors, self-complementary vectors, and dual glycan receptor. It focuses on the treatment of Duchenne muscular dystrophy, giant axonal neuropathy, Friedreich ataxia, and Canavan disease. Bamboo Therapeutics was founded by Richard Jude Samulski, Sheila A. Mikhail, Josh Grieger, Xiao Xiao, and Paola Leone in December 2014 and is headquartered in Chapel Hill, NC. | Health Technology |